Galena Biopharma, Inc. (GALE) Gets Multiple Mentions as Biotech Hot Stock; Set Up for Strong 2014
In the annual slew of evaluations of year-long stock performances, Galena Biopharma emerged as a strong biotech stock performer, posting triple-digit gains in the near-year-end period from 2011 to 2012 as well as 2012 to 2013. Articles published in outlets such as Seeking Alpha, Gaining Green, and iStreetWire noted that the biopharmaceutical company has generated some of the strongest returns in biotech stocks this year and last, with over 150% gains in December 2012 to December 2013 and over 300% gains in December 2011 to December 2012.
In particular, the iStreetWire article highlighted that Galena Biopharma made substantial gains with its development of several biopharmaceutical industry-bending cancer treatments. Many notable hedge funds added shares of the biopharmaceutical company to their portfolio holdings, a demonstration of the buzz the company has been receiving, as well as the prospective investment potential it may hold.
The company is currently making strong progress in its bring-to-market efforts of NeuVax™, a cancer immunotherapy that targets HER-2 presenting cells, a well-established point for cancer treatment. HER-2 is a tumor-associated antigen that is observable in different expressions of many types of human cancer cells. This immunotherapeutic solution harnesses the power of the immune system to target and destroy cancer cells that process HER-2 as well as inhibit any future appearances of these cells. This prospective medical breakthrough is currently in Phase III testing. If Galena Biopharma posts more positive developments in the immunotherapy’s clinical testing, its shares could generate further astronomic investor returns in 2014.
Earlier in 2013, Galena Biopharma acquired Abstral®, a sublingual tablet that enables patient management of breakthrough cancer pain, which is typically associated with patients who are receiving chronic, long-acting opioid pain management and nonetheless experience severe tumor-related and treatment-related cancer pain. The pain is most likely to occur when these patients engage in everyday activities, lowering daily life quality and task performance. Galena Biopharma’s acquisition of this pain-reducing medical innovation and its revenue-generating potential was a key factor for the company’s significant gains in the 2012 to 2013 near-year-end period.
Galena Biopharma is backed by the leadership of the company’s CEO and President Mark J. Ahn, PhD, an industry figure with over 20 years in the biopharmaceutical industry. Bolstered by a savvy, professionally diverse management team with a collective 80+ years of experience in the biopharmaceutical industry, the company may well indeed be positioned for a strong 2014, as consistent with its prior track record.
For more information, visit www.galenabiopharma.com
Please read full disclaimers at https://disclaimer.missionir.com